Shares of Calithera Biosciences Inc. (NASDAQ:CALA) rose 6% during trading on Monday . The company traded as high as $3.34 and last traded at $3.34, with a volume of 94,076 shares traded. The stock had previously closed at $3.15.

CALA has been the topic of a number of analyst reports. Wells Fargo & Co. reissued a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, May 12th. JMP Securities reissued a “buy” rating on shares of Calithera Biosciences in a research report on Wednesday, June 8th. Finally, Zacks Investment Research cut Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, May 17th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $10.38.

The stock’s 50-day moving average is $3.35 and its 200-day moving average is $4.81. The firm’s market cap is $59.52 million.

Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.03. Equities analysts anticipate that Calithera Biosciences Inc. will post ($2.16) earnings per share for the current fiscal year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.